Ying Jin

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Systemic Sclerosis

Histone Deacetylase

Top Venues

Nature medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

Signal transduction and targeted therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Ying Jin, Run-Jie Huang, Wen-Long Guan, Zhi-Qiang Wang, Zong-Jiong Mai, Yu-Hong Li, Jian Xiao, Xing Zhang, Qi Zhao, Shi-Fu Chen, Ming Liu, Yan-Xia Shi, Feng-Hua Wang, Rui-Hua Xu
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation. Signal transduction and targeted therapy 9 (1) (2024)
Feng-Hua Wang, Ming-Ming He, Jian Xiao, Yan-Qiao Zhang, Xiang-Lin Yuan, Wei-Jia Fang, Yan Zhang, Wei Wang, Xiao-Hua Hu, Zhi-Gang Ma, Yi-Chen Yao, Zhi-Xiang Zhuang, Yingying Shi, Jie-Er Ying, Ying Yuan, Qing-Feng Zou, Zeng Qing Guo, Xiang-Yuan Wu, Ying Jin, Zong-Jiong Mai, Zhi-Qiang Wang, Hong Qiu, Ying Guo, Si-Mei Shi, Shuang-Zhen Chen, Hui-Yan Luo, Dong-Sheng Zhang, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study). Clinical cancer research : an official journal of the American Association for Cancer Research 28 (19) (2022)
Liu-Fang Ye, Xiao-Meng Ji, Chao Ren, Zhi-Qiang Wang, Chun-Ping Lin, Dong-Liang Chen, Yan-Qing Cai, Ying Jin, Miao-Zheng Qiu, Zi-Ming Du, Shao-Yan Xi, Dong-Sheng Zhang, Feng Wang, Feng-Hua Wang, Rui-Hua Xu, Yu-Hong Li, De-Sheng Wang
The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis. Biomolecules 11 (9) (2021)